1. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). (June 2019) Authors: Sallman, David A.; Komrokji, Rami S.; Sweet, Kendra L.; Mo, Qianxing; McGraw, Kathy L.; Duong, Vu H.; Zhang, Ling; Nardelli, Lisa Ann; Padron, Eric; List, Alan F.; Lancet, Jeffrey E. Journal: Leukemia research Issue: Volume 81(2019) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Issue 8 (2nd July 2020) Authors: Duong, Vu H.; Al Ali, Najla; Zhang, Ling; Padron, Eric; Sallman, David; Lancet, Jeffrey E.; List, Alan F.; Komrokji, Rami S. Journal: Leukemia & lymphoma Issue: Volume 61:Issue 8(2020) Page Start: 1901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Abnormal monocyte differentiation and function in chronic myelomonocytic leukemia. Issue 1 (January 2022) Authors: Dhawan, Abhishek; Padron, Eric Journal: Current opinion in hematology Issue: Volume 29:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes. (30th August 2021) Authors: Song, Amy; Altabbakh, Omar; Sallman, David A.; Padron, Eric; Talati, Chetasi; Hussaini, Mohammad O. Journal: European journal of haematology Issue: Volume 107:Number 6(2021) Page Start: 609 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Issue 9 (September 2018) Authors: Basiorka, Ashley A; McGraw, Kathy L; Abbas-Aghababazadeh, Farnoosh; McLemore, Amy F; Vincelette, Nicole D; Ward, Grace A; Eksioglu, Erika A; Sallman, David A; Ali, Najla Al; Padron, Eric; Pinilla-Ibarz, Javier; Komrokji, Rami; Masala, Erico; Santini, Valeria; Kosmider, Olivier; Fontenay, Michaela... Journal: Lancet Issue: Volume 5:Issue 9(2018) Page Start: e393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. (23rd January 2018) Authors: McGraw, Kathy L.; Nguyen, Johnny; Al Ali, Najla H.; Komrokji, Rami S.; Sallman, David; Zhang, Xiaohui; Song, Jinming; Padron, Eric; Lancet, Jeffrey E.; Moscinski, Lynn C.; List, Alan F.; Zhang, Ling Journal: British journal of haematology Issue: Volume 184:Number 3(2019) Page Start: 450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Autoimmune diseases and myelodysplastic syndromes. Issue 5 (4th April 2016) Authors: Komrokji, Rami S.; Kulasekararaj, Austin; Al Ali, Najla H.; Kordasti, Shahram; Bart‐Smith, Emily; Craig, Benjamin M.; Padron, Eric; Zhang, Ling; Lancet, Jeffrey E.; Pinilla‐Ibarz, Javier; List, Alan F.; Mufti, Ghulam J.; Epling‐Burnette, Pearlie K. Journal: American journal of hematology Issue: Volume 91:Issue 5(2016:May) Page Start: E280 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double‐induction chemotherapy: Analysis from a large, single institution experience. Issue 3 (3rd February 2017) Authors: Griffin, Patrick T.; Komrokji, Rami S.; Sweet, Kendra; Al Ali, Najla H.; Padron, Eric; Kubal, Timothy E.; List, Alan F.; Lancet, Jeffrey E. Journal: American journal of hematology Issue: Volume 92:Issue 3(2017:Mar.) Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. (January 2023) Authors: Ball, Somedeb; Aguirre, Luis E.; Jain, Akriti G.; Ali, Najla Al; Tinsley, Sara M.; Chan, Onyee; Kuykendall, Andrew T.; Sweet, Kendra; Lancet, Jeffrey E.; Sallman, David A.; Hussaini, Mohammad Omar; Padron, Eric; Komrokji, Rami S. Journal: Leukemia research Issue: Volume 124(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. (March 2016) Authors: Suleiman, Yaman; Dalia, Samir; Liu, Jane Jijun; Bowers, Jeremy W.; Padron, Eric; Lancet, Jeffrey E.; Fulp, William; Moscinski, Lynn C.; Komrokji, Rami S.; Zuckerman, Kenneth S.; Zhang, Ling Journal: Leukemia research Issue: Volume 42(2016:Mar.) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗